Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,570,032
  • Shares Outstanding, K 370,856
  • Annual Sales, $ 9,625 M
  • Annual Income, $ -46,000 K
  • EBIT $ 2,945 M
  • EBITDA $ 4,349 M
  • 60-Month Beta 0.41
  • Price/Sales 0.28
  • Price/Cash Flow 0.95
  • Price/Book 7.69

Options Overview Details

View History
  • Implied Volatility 52.68% (-6.10%)
  • Historical Volatility 66.21%
  • IV Percentile 12%
  • IV Rank 4.26%
  • IV High 348.38% on 10/29/25
  • IV Low 39.53% on 03/19/25
  • Expected Move (DTE 4) 0.31 (4.54%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 2,703
  • Volume Avg (30-Day) 1,359
  • Put/Call OI Ratio 1.43
  • Today's Open Interest 141,172
  • Open Int (30-Day) 137,458
  • Expected Range 6.62 to 7.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.23
  • Number of Estimates 3
  • High Estimate 1.36
  • Low Estimate 1.13
  • Prior Year 1.15
  • Growth Rate Est. (year over year) +6.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.91 +17.26%
on 11/20/25
7.55 -8.21%
on 12/04/25
+0.15 (+2.21%)
since 11/05/25
3-Month
5.88 +17.96%
on 10/29/25
7.55 -8.21%
on 12/04/25
-0.42 (-5.71%)
since 09/05/25
52-Week
4.25 +63.06%
on 04/11/25
8.69 -20.21%
on 08/15/25
-1.19 (-14.66%)
since 12/05/24

Most Recent Stories

More News
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline

DRRX : 1.9100 (-1.04%)
BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat

Shares of Bausch Health Companies Inc. (BHC) declined 6.3% after the company reported mixed results for the second quarter of 2025.Adjusted earnings per share of 90 cents missed the Zacks Consensus Estimate...

DRRX : 1.9100 (-1.04%)
ARVN : 12.79 (+1.91%)
CRMD : 10.56 (-0.75%)
BHC : 6.93 (-6.10%)
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

LAVAL, QC and CUPERTINO, Calif. , July 29, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation...

DRRX : 1.9100 (-1.04%)
BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)
New Strong Sell Stocks for May 13th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:AlTi Global, Inc. ALTI is a financial company which provides merchant banking, corporate advisory, brokerage and placement agency...

AMRK : 29.25 (+1.88%)
BHC : 6.93 (-6.10%)
ALTI : 4.54 (+4.61%)
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down

Shares of Bausch Health Companies Inc. BHC declined 3.81% after the company reported lower-than-expected first-quarter 2025 results.Adjusted earnings per share of 59 cents missed the Zacks Consensus Estimate...

BEAM : 27.09 (-6.30%)
FOLD : 9.90 (-0.50%)
ADMA : 19.85 (-1.29%)
BHC : 6.93 (-6.10%)
Bausch Health Announces First Quarter 2025 Results

First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period

BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market

BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference

BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)
Bausch Health Announces Filing of Supplement to Proxy Statement

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares

BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today...

BHC.TO : 9.61 (-6.88%)
BHC : 6.93 (-6.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic...

See More

Key Turning Points

3rd Resistance Point 7.79
2nd Resistance Point 7.62
1st Resistance Point 7.27
Last Price 6.93
1st Support Level 6.75
2nd Support Level 6.58
3rd Support Level 6.23

See More

52-Week High 8.69
Fibonacci 61.8% 6.99
Last Price 6.93
Fibonacci 50% 6.47
Fibonacci 38.2% 5.94
52-Week Low 4.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar